NCT04634747View on ClinicalTrials.gov

Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

April 1, 2023

Study Completion Date

April 1, 2025

Conditions
Metastatic Triple-Negative Breast Carcinoma
Interventions
DRUG

PVX-410

PVX-410 in combination with pembrolizumab and chemotherapy

Sponsors

Lead Sponsor

OncoPep, Inc.
All Listed Sponsors
lead

OncoPep, Inc.

INDUSTRY

NCT04634747 - Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter